Shrideavi Murugan

Ms. Shrideavi Murugan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
Madhan JeyaramanMadhan Jeyaraman
Madhan Jeyaraman
NJNaveen Jeyaraman
Naveen Jeyaraman
ANArulkumar Nallakumarasamy
Arulkumar Nallakumarasamy
SRSwaminathan Ramasubramanian
Swaminathan Ramasubramanian
Sathish MuthuSathish Muthu
Sathish Muthu
Prakash GangadaranPrakash Gangadaran
Prakash Gangadaran

14 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NJNaveen Jeyaraman
Naveen Jeyaraman
Filippo MiglioriniFilippo Migliorini
Filippo Migliorini
SMShrideavi Murugan
Shrideavi Murugan
SRSwaminathan Ramasubramanian
Swaminathan Ramasubramanian
SBSangeetha Balaji
Sangeetha Balaji
Madhan JeyaramanMadhan Jeyaraman
Madhan Jeyaraman
Metamizole, or dipyrone, has been used for decades as a non-narcotic analgesic, providing pain relief from musculoskeletal disorders and antipyretic and antispasmolytic properties. Despite being in use since the 1920s, its mechanism of action still needs to be discovered. Despite causing fewer adverse effects when compared to other analgesics, its harmful effects on the blood and lack of evidence regarding its teratogenicity make the usage of the drug questionable, which has led to it being removed from the drug market of various countries. This narrative review aims to provide a detailed insight into the mechanism of action and efficacy, comparing its effectiveness and safety with other classes of drugs and the safety profile of metamizole.

21 January 2025 in European Burn Journal
Verified
Journal Article
Open access
PDF file
Madhan JeyaramanMadhan Jeyaraman
Madhan Jeyaraman
NJNaveen Jeyaraman
Naveen Jeyaraman
SRSwaminathan Ramasubramanian
Swaminathan Ramasubramanian
ANArulkumar Nallakumarasamy
Arulkumar Nallakumarasamy
SMShrideavi Murugan
Shrideavi Murugan
Sathish MuthuSathish Muthu
Sathish Muthu
Surgical site infections (SSIs) are a significant challenge in postoperative care, leading to increased morbidity, extended hospital stays, and elevated healthcare costs. Traditional antimicrobial dressings, such as those containing silver or iodine, have limitations, including cytotoxicity and the potential for antimicrobial resistance. Dialkylcarbamoyl chloride (DACC)-impregnated dressings offer a novel approach, employing a physical mechanism to bind and remove bacteria without the use of chemical agents, thereby reducing the risk of resistance. This review summarizes current evidence on the efficacy of DACC dressings in preventing SSIs and promoting wound healing. Findings from multiple studies indicate that DACC dressings reduce bacterial burden and SSI rates across various surgical procedures, including cesarean sections and vascular surgeries. Additionally, DACC dressings demonstrate potential in managing hard-to-heal wounds, such as diabetic foot ulcers, by reducing bacterial load and biofilm formation. Furthermore, they present advantages in antimicrobial stewardship and cost-effectiveness by minimizing the need for antibiotics and decreasing overall healthcare expenses. However, the current literature is limited by small sample sizes, methodological weaknesses, heterogeneity in study designs, and a lack of long-term data. Future research should focus on high-quality randomized controlled trials across diverse surgical populations, comprehensive cost-effectiveness analyses, and long-term outcomes to establish the full clinical impact of DACC dressings. With further validation, DACC-impregnated dressings could become a critical tool in sustainable postoperative wound care.